Cancer Clinical Trial
— ALCINA4Official title:
Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4
Multi-cohort exploratory prospective study. Participation in the ALCINA 4 study does not change the standard management of the patient, including the treatments administered. A sampling schedule will be set up for each cohort. Depending on the clinical context studied and the biomarkers studied and/or sought, the timing of blood samples will vary between cohorts. There may be up to 4 samples taken per patient for up to 12 or 18 months. If a specific tumor sample is required, it will be collected only once during the study.
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | June 1, 2031 |
Est. primary completion date | June 1, 2031 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient treated for cancer at one of the participating center - 18 years old or higher - Signed informed consent form - Patient not deprived of their liberty or under guardianship (including temporary guardianship) - Patient covered by social security scheme - Patient with no compliance issue (related to geographical, social or psychological reasons) for study follow up - Other additional criteria will be defined (defining tumor type and clinical setting), by cohort If a biopsy tumor sample is to be taken: - Tumor considered as accessible by biopsy (at the investigator's discretion). - Normal blood coagulation tests (if applicable, and in case of a non-superficial tumor lesion). - No anticoagulant or antiaggregant treatment for the biopsy. |
Country | Name | City | State |
---|---|---|---|
France | Institut Curie | Paris | |
France | Institut Curie | Saint-cloud |
Lead Sponsor | Collaborator |
---|---|
Institut Curie |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Detection rate of circulating biomarkers in cohort 1 | Positivity rate of the detection technique (in %) | Baseline | |
Primary | Detection rate of circulating biomarkers in cohort 2 | Positivity rate of the detection technique (in %) | Baseline | |
Primary | Detection rate of circulating biomarkers in cohort 2 | Positivity rate of the detection technique (in %) | Before treatment | |
Primary | Detection rate of circulating biomarkers in cohort 2 | Positivity rate of the detection technique (in %) | At 3 weeks of treatment | |
Primary | Detection rate of circulating biomarkers in cohort 2 | Positivity rate of the detection technique (in %) | At 9 weeks of treatment | |
Primary | Detection rate of circulating biomarkers in cohort 2 | Positivity rate of the detection technique (in %) | At disease progression | |
Primary | Detection rate of circulating biomarkers in cohort 1 | Positivity rate of the detection technique (in %) | Before surgery | |
Primary | Detection rate of circulating biomarkers in cohort 1 | Positivity rate of the detection technique (in %) | After surgery (from 3 to 5 weeks) | |
Primary | Detection rate of circulating biomarkers in cohort 1 | Positivity rate of the detection technique (in %) | After surgery (from 2 to 3 months) | |
Primary | Detection rate of circulating biomarkers in cohort 3 | Positivity rate of the detection technique (in %) | Baseline | |
Primary | Detection rate of circulating biomarkers in cohort 3 | Positivity rate of the detection technique (in %) | At the end of cycle 1 (each cycle is 21 days) | |
Primary | Detection rate of circulating biomarkers in cohort 3 | Positivity rate of the detection technique (in %) | After surgery (from 2 to 3 months) | |
Primary | Detection rate of circulating biomarkers in cohort 3 | Positivity rate of the detection technique (in %) | At disease progression | |
Primary | Detection rate of circulating biomarkers in cohort 4 | Positivity rate of the detection technique (in %) | At pre-surgery or before starting treatment | |
Primary | Detection rate of circulating biomarkers in cohort 4 | Positivity rate of the detection technique (in %) | At 6 weeks after surgery or after start of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|